Comparison of long-term drug survival and safety of biologic agents in patients with moderate- to-severe psoriasis vulgaris

Background: Biologic therapies have significantly advanced the management of moderate- to-severe chronic psoriasis. Biologics targeting Tumor Necrosis Factor (TNF)-a, Interleukin (IL)-17, IL-23, and IL-12/23 have emerged as an important treatment option. However, data on long-term outcomes and safety profiles of the biologics in daily practice are limited.